Gutron

Gutron is a prescription medication that contains the active ingredient Midodrine Hydrochloride, supplied in an oral dosage form for use in the European Union. It belongs to the alpha‑adrenergic agonist class and is indicated for the management of orthostatic hypotension, a condition characterized by a significant drop in blood pressure upon standing.

Gutron is prescribed to help patients who experience low blood pressure when moving to an upright position. It is used in clinical practice to improve standing blood pressure and reduce symptoms such as dizziness or fainting.

- Treatment of orthostatic hypotension in adults - Management of symptomatic low standing blood pressure - Adjunct therapy when non‑pharmacologic measures are insufficient - Support for patients with neurogenic causes of blood pressure drop

Side effects of Gutron can vary in frequency and severity. Common reactions are usually mild, while serious events are less frequent but require medical attention.

Common: - Piloerection (goosebumps) - Pruritus (itching) - Urinary urgency or frequency - Scalp tingling or flushing - Supine hypertension (elevated blood pressure while lying down)

Serious: - Severe supine hypertension leading to cardiovascular risk - Allergic reactions such as rash or angioedema - Chest pain or palpitations - Persistent headache

Before starting Gutron, certain health considerations should be reviewed to ensure safe use. Patients and clinicians should be aware of the following precautions: - Assess for existing hypertension, especially supine hypertension - Evaluate renal or hepatic impairment, which may affect drug metabolism - Review cardiovascular history, including heart failure or arrhythmias - Caution in patients with urinary retention or bladder outlet obstruction - Discuss pregnancy and lactation status, as safety data are limited - Monitor blood pressure regularly after dose adjustments

Gutron may interact with other medications, influencing its effectiveness or increasing the risk of adverse effects. Interaction guidance includes:

Avoid: - Other vasoconstrictors or sympathomimetic agents that may exacerbate hypertension - Monoamine oxidase inhibitors (MAOIs) taken within 14 days of Gutron - Direct-acting alpha‑agonists such as phenylephrine

Use with caution: - Antihypertensive drugs (e.g., ACE inhibitors, beta‑blockers) that could lower blood pressure excessively - Diuretics, which may affect fluid balance and blood pressure - Central nervous system depressants that may mask symptoms of hypotension